Mitsubishi Tanabe to buy Israel's NeuroDerm for $1.1 bn

July 24, 2017

Japan's Mitsubishi Tanabe Pharma announced Monday a billion-dollar deal to buy an Israeli company that specialises in developing treatments for Parkinson's disease.

The Osaka-based firm said it will acquire all of Nasdaq-listed NeuroDerm's outstanding shares for $1.1 billion at a price of $39 per share.

The deal is subject to approval by NeuroDerm shareholders as well as regulatory approval.

NeuroDerm develops treatments for patients suffering from Parkinson's disease, as well as other disorders related to the central nervous system.

The company, which has been supported by grants from the Michael J Fox Foundation for Parkinson's Research, aims to radically change the way the disease is treated through reformulating existing drugs.

Its current lead product candidate is in advanced in Europe and the United States and could hit the market as early as 2019, Mitsubishi Tanabe said.

Explore further: Elan enters $1B royalty deal with Theravance

Related Stories

Elan enters $1B royalty deal with Theravance

May 13, 2013
Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

Scientific discovery may change treatment of Parkinson's disease

March 22, 2017
When monitoring Parkinson's disease, SPECT imaging of the brain is used for acquiring information on the dopamine activity. A new study conducted in Turku, Finland, shows that the dopamine activity observed in SPECT imaging ...

Horizon Pharma to pay $800M for rare disease drug developer

September 12, 2016
Horizon Pharma will spend about $800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers.

Adamas Pharma rises after IPO raises $48 million

April 10, 2014
Shares of Adamas Pharmaceuticals rose Thursday after the drug developer's initial public offering raised $48 million.

AmerisourceBergen expands into animal health with $2.5B deal

January 12, 2015
Pharmaceutical distributor AmerisourceBergen will stretch its reach into veterinary medicine by spending about $2.5 billion to acquire MWI Veterinary Supply.

Teva buying Auspex for $3.2 billion

March 30, 2015
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Recommended for you

Researchers find new path to promising Parkinson's treatment

September 19, 2017
Three researchers at The University of Alabama are part of work that is leading to a new direction for drug discovery in the quest to treat Parkinson's disease.

Tug of war between Parkinson's protein and growth factor

September 18, 2017
Alpha-synuclein, a sticky and sometimes toxic protein involved in Parkinson's disease (PD), blocks signals from an important brain growth factor, Emory researchers have discovered.

Medical history can point to earlier Parkinson's disease diagnosis

September 15, 2017
Before symptoms become pronounced, there is no reliable way to identify who is on track to develop Parkinson's disease, a debilitating movement disorder characterized by tremors, slowness of movement, stiffness, and difficulty ...

Brain rewiring in Parkinson's disease may contribute to abnormal movement

September 14, 2017
The brain's own mechanisms for dealing with the loss of dopamine neurons in Parkinson's disease may be a source of the disorder's abnormal movement, according to a Northwestern Medicine study published in Neuron.

Treating with antioxidants early in Parkinson's disease process may halt degeneration and improve neuronal function

September 7, 2017
Northwestern Medicine scientists have identified a toxic cascade that leads to neuronal degeneration in patients with Parkinson's disease (PD) and figured out how to interrupt it, reports a study to be published September ...

New diagnostic tool spots first signs of Parkinson's disease

September 6, 2017
Researchers have developed the first tool that can diagnose Parkinson's disease when there are no physical symptoms, offering hope for more effective treatment of the condition.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.